Specifically our signature demonstrated significant overlap with those observed for tamoxifen, fulvestrant and aromatase inhibitor resistance in multiple breast cancer cell lines including long term estrogen deprived (LTED) cells [24], [25], [26], [27] . This evidence concerns the gene CYP19A1 and breast cancer.